Analyst on possible AstaZeneca-Gilead deal: Strange at first sight, but maybe not that much

AstraZeneca approached drugmaker Gilead about a potential merger. Michael Leuchten Head of Equity Research at UBS joins Yahoo Finance’s On The Move to discuss.